Examkin

Soru

Zorluk: ZorPharmacologic Interventions

A 72-year-old woman is admitted to the hospital due to progressively worsening shortness of breath, orthopnea, and lower extremity swelling over the past four days. Her medical history is significant for ischemic cardiomyopathy with a documented left ventricular ejection fraction of 25%, type 2 diabetes mellitus, and chronic kidney disease. On triage, her temperature is 37.1°C (98.8°F), blood pressure is 102/68 mm Hg, heart rate is 148/min and irregular, respiratory rate is 24/min, and oxygen saturation is 91% on room air. Physical examination reveals elevated jugular venous pressure to 11 cm H2OH_2O, bibasilar crackles extending to the mid-lung fields, and 3+ bilateral pitting edema. An electrocardiogram is obtained and demonstrates a narrow-complex, irregularly irregular tachycardia lacking distinct P waves. She is placed on supplemental oxygen and intravenous bumetanide is prescribed. Which of the following pharmacologic agents are appropriate for immediate intravenous rate control of this patient's arrhythmia? (Select all that apply)

  1. Intravenous amiodaroneCevap
  2. Intravenous digoxinCevap
  3. C
    Intravenous diltiazem
  4. D
    Intravenous metoprolol tartrate
  5. E
    Intravenous adenosine

Cevap

The correct interventions are intravenous amiodarone and intravenous digoxin.
The correct options are intravenous amiodarone and intravenous digoxin. This patient is experiencing atrial fibrillation with a rapid ventricular response, complicated by acute decompensated heart failure (ADHF) in the setting of known heart failure with reduced ejection fraction (HFrEF). The management of rapid atrial fibrillation in ADHF requires careful selection of rate-controlling agents to avoid worsening the patient's fragile hemodynamic state. Both amiodarone and digoxin effectively slow conduction through the atrioventricular (AV) node without exerting clinically significant negative inotropic effects. Consequently, they are the preferred pharmacological interventions for acute rate control in patients with left ventricular systolic dysfunction who are actively decompensated.

Adım Adım Çözüm

1
Identify the primary arrhythmia.
The ECG findings of an irregularly irregular, narrow-complex tachycardia without P waves confirm the diagnosis of atrial fibrillation with rapid ventricular response.
Establishing the correct rhythm is the first step in determining the appropriate antiarrhythmic pathway.
2
Assess the patient's hemodynamic status and coexisting conditions.
The patient has a known history of heart failure with reduced ejection fraction (HFrEF) and presents with acute volume overload (elevated jugular venous pressure, crackles, edema), indicating acute decompensated heart failure.
Coexisting acute decompensated heart failure severely restricts the choice of rate-controlling medications due to the risk of cardiovascular collapse from negative inotropes.
3
Select rate-control agents lacking negative inotropic effects.
Intravenous digoxin and intravenous amiodarone are selected as they slow atrioventricular node conduction without suppressing myocardial contractility.
Standard rate-control agents (beta-blockers, non-dihydropyridine calcium channel blockers) are contraindicated in this specific clinical context.

Anahtar Kavram

In patients presenting with atrial fibrillation with rapid ventricular response in the setting of acute decompensated heart failure with reduced ejection fraction, rate control must be achieved using agents lacking negative inotropic effects, specifically intravenous digoxin or amiodarone.
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru